What is Greenwich LifeSciences, Inc.'s (GLSI) StockRank?

MoatMap's StockRank for Greenwich LifeSciences, Inc. (GLSI) is 28/100, with a Sell signal. This is a composite score combining Quality (19), Value (33), and Momentum (68) factor ranks across MoatMap's 19,000+ stock universe.

Does Greenwich LifeSciences, Inc. have an economic moat?

Greenwich LifeSciences, Inc. (GLSI) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Greenwich LifeSciences, Inc. a buy, hold, or sell?

MoatMap's current signal for Greenwich LifeSciences, Inc. (GLSI) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Greenwich LifeSciences, Inc. in?

Greenwich LifeSciences, Inc. (GLSI) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

GLSI

SELLREMOVE

Greenwich LifeSciences, Inc. · Healthcare · United States · $402M · Avg Vol: $3M/d

StockRank

P/E (TTM)

—

ROE

-676.7%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Greenwich LifeSciences is a clinical-stage biotechnology company. It is highly speculative, lacks revenues, and does not possess the validated, high-utilization manufacturing assets that define our CDMO pricing power theme.

COMPANY DESCRIPTION

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. The company's competitive position is anchored by its ongoing Phase III clinical trial (FLAMINGO-01) targeting HER2/neu-positive breast cancer. As a niche oncology player, Greenwich operates with a highly focused pipeline aimed at addressing unmet needs in post-surgical cancer care.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.61	-0.69	-1.34	-1.43	—
Shares	13M	13M	13M	14M	+11.3%
Debt	262,905	294,406	3M	6M	180.9%
Equity	13M	7M	908,626	353,217	-70.1%
Op CF	-6M	-6M	-7M	-10M	—
Inv CF	—	—	—	—	—
Fin CF	-8M	0	4M	12M	—

PRICE (1M)+6.5%

SMA 50SMA 200

$23.41

RSI (14)

38.6

52W High

$34.10

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-631.9%0.3

ROE

-676.7%0.9

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-83.1%1.8

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

2.01x36.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-15.3x85.1

P/FCF

—N/A

P/B

67.0x1.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

69%54.9

RS 6M

99%97.7

SMA 50/200

1.30x94.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+49%53.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$402M

P/E (Forward)

-29.3x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GLSI are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
GLSI	Greenwich LifeSciences, Inc.(you)	$402M	28	SELL
ENTA	Enanta Pharmaceuticals, Inc.	$385M	28	SELL
BNTC	Benitec Biopharma Inc.	$397M	29	SELL
STTK	Shattuck Labs, Inc.	$458M	30	SELL
SGMT	Sagimet Biosciences Inc.	$449M	27	SELL
FDMT	4D Molecular Therapeutics, Inc.	$469M	30	SELL
LRMR	Larimar Therapeutics, Inc.	$363M	23	SELL
NAUT	Nautilus Biotechnology, Inc.	$330M	33	SELL
PALI	Palisade Bio, Inc.	$358M	35	SELL
ACHV	Achieve Life Sciences, Inc.	$544M	31	SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Greenwich LifeSciences, Inc. (GLSI) — Stock Score Summary

Greenwich LifeSciences, Inc. (GLSI) has a MoatMap StockRank of 28/100 based on Quality (19/100), Value (33/100), and Momentum (68/100) factor scores. The current signal is SELL. Greenwich LifeSciences is a clinical-stage biotechnology company. It is highly speculative, lacks revenues, and does not possess the validated, high-utilization manufacturing assets that define our CDMO pricing power theme.

Key Financial Metrics

Price	$23.41
Market Cap	$402M
P/E (Forward)	-29.34
Price/Book	67.02
Return on Equity	-676.7%
Return on Invested Capital	-631.9%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-3M

Greenwich LifeSciences, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Greenwich LifeSciences, Inc.’s (GLSI) StockRank?: MoatMap’s StockRank for Greenwich LifeSciences, Inc. (GLSI) is 28/100, with a Sell signal. It is a composite of Quality (19), Value (33), and Momentum (68) factor ranks across MoatMap’s 19,000+ stock universe.
Does Greenwich LifeSciences, Inc. have an economic moat?: Greenwich LifeSciences, Inc. (GLSI) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Greenwich LifeSciences, Inc. a buy, hold, or sell?: MoatMap’s current signal for Greenwich LifeSciences, Inc. (GLSI) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Greenwich LifeSciences, Inc. in?: Greenwich LifeSciences, Inc. (GLSI) operates in the Healthcare sector, specifically the Biotechnology industry (United States).